Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Exercise Over-allotment Option on Cancer Genetics IPO

NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market on Friday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase 90,000 additional shares of its stock at $10 per share.

As a result, the total gross proceeds from the offering are expected to be $6.9 million, Cancer Genetics said.

Aegis Capital was the sole book-running manager on the offering while Feltl and Co. acted as the co-manager.

The Rutherford, NJ-based cancer diagnostics firm went public last week, offering 600,000 shares of its stock at $10 per share. Cancer Genetics trades on the OTCQB Marketplace under ticker symbol "CGIX".

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.